All In Biotech

Drug Trial Radar · NCT00146328

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects

Last checked: Nov 20, 2026Latest source record: Mar 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

997

Actual

Start

Apr 2001

Primary completion

May 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.

Conditions

  • HIV Infections

Interventions

  • TipranavirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - HaemoglobinTime frame: End of Trial (>288 weeks)
  2. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - White Blood Cell ct.Time frame: End of Trial (>288 weeks)
  3. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - PlateletsTime frame: End of Trial (>288 weeks)
  4. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Prothrombin TimeTime frame: End of Trial (>288 weeks)
  5. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - SodiumTime frame: End of Trial (>288 weeks)
  6. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - PotassiumTime frame: End of Trial (>288 weeks)
  7. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - CalciumTime frame: End of Trial (>288 weeks)
  8. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - PhosphateTime frame: End of Trial (>288 weeks)
  9. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Carbon DioxideTime frame: End of Trial (>288 weeks)
  10. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Aspartate Aminotransferase (AST/GOT,SGOT)Time frame: End of Trial (>288 weeks)
  11. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alanine Aminotransferase (ALT/GPT,SGPT)Time frame: End of Trial (>288 weeks)
  12. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alkaline PhosphataseTime frame: End of Trial (>288 weeks)
  13. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - AmylaseTime frame: End of Trial (>288 weeks)
  14. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatine PhosphokinaseTime frame: End of Trial (>288 weeks)
  15. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - LipaseTime frame: End of Trial (>288 weeks)
  16. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - GlucoseTime frame: End of Trial (>288 weeks)
  17. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Cholesterol, TotalTime frame: End of Trial (>288 weeks)
  18. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - CreatinineTime frame: End of Trial (>288 weeks)
  19. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Bilirubin, TotalTime frame: End of Trial (>288 weeks)
  20. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - TriglyceridesTime frame: End of Trial (>288 weeks)
  21. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Uric AcidTime frame: End of Trial (>288 weeks)
  22. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - AlbuminTime frame: End of Trial (>288 weeks)
  23. Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 -Low-density Lipoprotein (LDL)Time frame: End of Trial (>288 weeks)
  24. Number of Patients With Adverse Events Leading to DeathTime frame: End of Trial (>288 weeks)

Locations

233 sites in 18 countries. Site status is shown where the registry gives one.

  • 1182.17.39 MDS Pharma Services

    Phoenix, Arizona

  • 1182.17.75 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 1182.17.89 Boehringer Ingelheim Investigational Site

    Berkeley, California

  • 1182.17.60 Boehringer Ingelheim Investigational Site

    Fountain Valley, California

  • 1182.17.106 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1182.17.15 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1182.17.40 Tower ID Medical

    Los Angeles, California

  • 1182.17.46 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1182.17.47 University of Southern California

    Los Angeles, California

  • 1182.17.73 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1182.17.114 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1182.17.128 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1182.17.37 Boehringer Ingelheim Investigational Site

    San Francisco, California

  • 1182.17.58 Boehringer Ingelheim Investigational Site

    San Francisco, California

  • 1182.17.96 Boehringer Ingelheim Investigational Site

    San Francisco, California

  • 1182.17.87 Boehringer Ingelheim Investigational Site

    Norwalk, Connecticut

  • 1182.17.112 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 1182.17.43 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 1182.17.65 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 1182.17.126 Boehringer Ingelheim Investigational Site

    Fort Lauderdale, Florida

  • 1182.17.8 Boehringer Ingelheim Investigational Site

    Fort Myers, Florida

  • 1182.17.131 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1182.17.22 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1182.17.64 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 1182.17.129 Boehringer Ingelheim Investigational Site

    Sarasota, Florida

  • 1182.17.51 Boehringer Ingelheim Investigational Site

    South Miami, Florida

  • 1182.17.125 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1182.17.132 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1182.17.76 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1182.17.52 Boehringer Ingelheim Investigational Site

    Vero Beach, Florida

  • 1182.17.77 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 1182.17.69 Boehringer Ingelheim Investigational Site

    Macon, Georgia

  • 1182.17.136 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 1182.17.70 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 1182.17.36 Boehringer Ingelheim Investigational Site

    Evanston, Illinois

  • 1182.17.1 Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • 1182.17.32 University of Kansas School of Medicine - Wichita

    Wichita, Kansas

  • 1182.17.102 Boehringer Ingelheim Investigational Site

    Lexington, Kentucky

  • 1182.17.21 Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • 1182.17.30 Boehringer Ingelheim Investigational Site

    Portland, Maine

Showing 40 of 233 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.